Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.49 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 2/20 | 0.46 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CDA | P32320 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157193 | 1.00 | PYGM (0.49) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL41006 | 0.88 | PYGM (0.63) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL14853801 | 0.88 | PYGM (0.63) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18503552 | 0.88 | PYGM (0.63) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL41007 | 0.88 | PYGM (0.63) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL14929134 | 0.88 | PYGM (0.63) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18512922 | 0.88 | PYGM (0.63) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL26369663 | 0.86 | PYGM (0.52) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL157586 | 0.86 | PYGM (0.52) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL157587 | 0.86 | PYGM (0.52) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2973 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250295744-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS | BioNTech SE (DE) | 2025-09-25 | — | — | US | claimed |
| US-20250277223-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES | IMCYSE SA (BE) | 2025-09-04 | — | — | US | claimed |
| US-12398379-B2 | Compositions and methods for treating ornithine transcarbamylase deficiency | ARCTURUS THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| EP-3609529-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | BioNTech RNA Pharmaceuticals GmbH (DE) | 2020-02-19 | — | — | EP | claimed |
| CN-110719787-A | RNA for treating autoimmune diseases | 生物技术RNA制药有限公司 | 2020-01-21 | — | — | CN | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| WO-2018188730-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2018-10-18 | — | — | WO | claimed |
| WO-2018189193-A1 | RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2018-10-18 | — | — | WO | claimed |
| EP-3387150-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2018-10-17 | — | — | EP | claimed |
| US-9719084-B2 | Co-transcriptional assembly of modified RNA nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-08-01 | — | — | US | claimed |
| WO-2017098468-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2017-06-15 | — | — | WO | claimed |
| US-20150203842-A1 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2015-07-23 | — | — | US | claimed |
| EP-2578685-A2 | RNA containing modified nucleosides and methods of use thereof | The Trustees of The University of Pennsylvania (US) | 2013-04-10 | — | — | EP | claimed |